Cargando…
Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective
IMPORTANCE: Diabetic foot ulcers (DFUs) and subsequent amputation incur enormous health and economic burdens to patients, health care systems, and societies. As a novel macrophage-regulating drug, ON101 is a breakthrough treatment for DFUs, which demonstrated significant complete wound healing effec...
Autores principales: | Su, Hsuan-Yu, Yang, Chen-Yi, Ou, Huang-Tz, Chen, Shyi-Gen, Chen, Jui-Ching, Ho, Hui-Ju, Kuo, Shihchen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856772/ https://www.ncbi.nlm.nih.gov/pubmed/36633847 http://dx.doi.org/10.1001/jamanetworkopen.2022.50639 |
Ejemplares similares
-
New Horizons of Macrophage Immunomodulation in the Healing of Diabetic Foot Ulcers
por: Lin, Ching-Wen, et al.
Publicado: (2022) -
Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers: A Randomized Clinical Trial
por: Huang, Yu-Yao, et al.
Publicado: (2021) -
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021) -
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020) -
Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan
por: Peng, Zi-Yang, et al.
Publicado: (2022)